Sanofi (NASDAQ:SNY) Holdings Lowered by Eagle Asset Management Inc.

Eagle Asset Management Inc. trimmed its stake in shares of Sanofi (NASDAQ:SNYFree Report) by 4.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,054 shares of the company’s stock after selling 309 shares during the quarter. Eagle Asset Management Inc.’s holdings in Sanofi were worth $301,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Brandes Investment Partners LP raised its holdings in shares of Sanofi by 64.6% in the 4th quarter. Brandes Investment Partners LP now owns 1,770,572 shares of the company’s stock worth $88,051,000 after purchasing an additional 694,957 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Sanofi by 29.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after purchasing an additional 651,756 shares in the last quarter. Natixis Advisors L.P. raised its holdings in shares of Sanofi by 15.9% in the 3rd quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock worth $135,618,000 after purchasing an additional 346,563 shares in the last quarter. Morgan Stanley raised its holdings in shares of Sanofi by 4.6% in the 3rd quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock worth $392,796,000 after purchasing an additional 323,968 shares in the last quarter. Finally, Clough Capital Partners L P bought a new stake in shares of Sanofi in the 3rd quarter worth approximately $14,719,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $49.13 on Thursday. The firm’s 50 day simple moving average is $48.28 and its 200-day simple moving average is $48.40. The company has a market cap of $124.29 billion, a P/E ratio of 24.69, a price-to-earnings-growth ratio of 1.54 and a beta of 0.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $55.72.

Sanofi (NASDAQ:SNYGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.96 EPS for the quarter, meeting analysts’ consensus estimates of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. The firm had revenue of $11.36 billion for the quarter, compared to the consensus estimate of $11.75 billion. As a group, equities research analysts predict that Sanofi will post 4.11 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. Sanofi’s payout ratio is presently 74.37%.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research reports. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Get Our Latest Stock Report on SNY

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.